Injectable GLP-1 medications require refrigeration
Patients should be counseled never to administer extra doses to make up for missed doses, as this could increase the risk of adverse effects without providing additional therapeutic benefit
Diosgenin: An Updated Pharmacological Review and Therapeutic Perspectives
Foundayo contains orforglipron, a completely different small-molecule GLP1 agonist developed by Eli Lilly
Side effects and safety profile Across the combined Phase 3 Tesamorelin database of over 800 treated subjects, the most frequently reported adverse events were injection site reactions (erythema, pruritus, small local hematoma) at roughly 25 percent of subjects, arthralgia and myalgia at 10 to 15 percent, and peripheral edema at 6 to 8 percent
The child knows what to expect